Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 1/2 1

Status

Recruiting 1Not yet recruiting 1

Sponsor Class

OTHER 2

Study Type

Interventional 2Observational 1

Sponsor

Cancer Type

Genitourinary 2

Conditions

Breast Neoplasms 2433Neoplasms 1842Carcinoma, Non-Small-Cell Lung 1609Prostatic Neoplasms 1312Colorectal Neoplasms 1144Lung Neoplasms 991Neoplasm Metastasis 835Multiple Myeloma 800Leukemia, Myeloid, Acute 778Ovarian Neoplasms 685Pancreatic Neoplasms 671Melanoma 667Squamous Cell Carcinoma of Head and Neck 592Carcinoma, Hepatocellular 570Recurrence 568Brain Neoplasms 528Glioblastoma 519Stomach Neoplasms 503Head and Neck Neoplasms 502Triple Negative Breast Neoplasms 473Lymphoma 461Uterine Cervical Neoplasms 457Carcinoma, Renal Cell 429Precursor Cell Lymphoblastic Leukemia-Lymphoma 421Lymphoma, Non-Hodgkin 390Endometrial Neoplasms 386Sarcoma 369Urinary Bladder Neoplasms 356Lymphoma, Large B-Cell, Diffuse 356Lymphoma, Follicular 356

Interventions

enfortumab vedotin 2pembrolizumab 1Radiotherapy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Interventional × Advanced Bladder Cancer × 1 year × Clear all
NCT06434350 2026-03-02

Enfortumab Vedotin With Radiation for Locally Advanced Bladder Cancer (CONSOLIDATE)

M.D. Anderson Cancer Center

Phase 1/2 Recruiting
41 enrolled
Genitourinary

Advanced Bladder Cancer

NCT07346053 2026-01-16

Chrono-EVP

British Columbia Cancer Agency

Phase 3 Not yet recruiting
224 enrolled
Genitourinary

Advanced Bladder Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡